



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

November 24, 2020

R. Kirk Huntsman  
Chief Executive Officer  
Vivos Therapeutics, Inc.  
9137 Ridgeline Boulevard, Suite 135  
Highlands Ranch, Colorado 80129

**Re: Vivos Therapeutics, Inc.**  
**Amendment No. 2 to Registration Statement on Form S-1**  
**Filed November 19, 2020**  
**File No. 333-249412**

Dear Mr. Huntsman:

We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments.

Amendment No. 2 to Registration Statement on Form S-1

Prospectus Summary

Overview, page 2

1. We note your new disclosure on page 2 indicating that the Vivos System led to lower mean AHI scores by up to 69.6% in patients with varying degrees of OSA as well as the five studies cited in your table and your statement that you are not aware of any additional published studies that evaluate the impact of the Vivos System on AHI scores in patients with OSA.

We further note your statement on page 1 indicating that there are 17 peer-reviewed studies that examined the impact of your "technologies and protocols" on the AHI scores of patients with varying degrees of OSA, that patient AHI scores were reduced from a low

R. Kirk Huntsman  
Vivos Therapeutics, Inc.  
November 24, 2020  
Page 2

of 38% to a high of 98.6% and that you are not aware of any additional published studies evaluating the impact of the Vivos System on AHI scores in patients with OSA.

Please revise your disclosure to reconcile your presentation of these studies including whether "published studies" and "peer-reviewed studies" are terms for the same type of study and, if not, the difference between a "published study" and a "peer-reviewed" study.

Executive Compensation

October 2020 Derivative Demand and Settlement, page 107

2. We note your statement that the Demanding Stockholders asked your board of directors to review and investigate certain actions taken by your board of directors and senior management, including actions related to the IPO, the rejection of a transaction proposal, management of corporate assets and matters related to stock sales. We further note your statement at the beginning of the following paragraph which refers to "assertions" made by the Demanding Stockholders. Please revise your disclosure to clarify what those "assertions" were.

Please also file the Settlement and Release Agreement as an exhibit to your registration statement or explain to us why it is not required to be filed.

Finally, we note that your cross-references elsewhere in the document state that this disclosure appears in the Business section. Please correct those cross-references or move this disclosure to Business.

You may contact Michael Fay at 202-551-3812 or Kevin Kuhar at 202-551-3662 if you have questions regarding comments on the financial statements and related matters. Please contact Alan Campbell at 202-551-4224 or Tim Buchmiller at 202-551-3635 with any other questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Lawrence A. Rosenbloom, Esq.